Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 4/20 | 0.40 |
| ▸ | ACACA | Q13085 | 4/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384319 | 0.90 | SLC6A12 (0.41) | CKS1BSKP1SKP2KMT2AL3MBTL1 | |
| SCHEMBL25961451 | 0.82 | ALDH1A1 (0.44) | KMT2AL3MBTL1 | |
| SCHEMBL29998568 | 0.81 | CKS1B (0.57) | CKS1BSKP1SKP2KMT2AL3MBTL1 | |
| SCHEMBL27448755 | 0.81 | CKS1B (0.57) | CKS1BSKP1SKP2KMT2AL3MBTL1 | |
| SCHEMBL9430749 | 0.75 | KMT2A (0.60) | KMT2AL3MBTL1BTKKCNA3DRD2 | |
| SCHEMBL3830180 | 0.75 | KMT2A (0.60) | KMT2AL3MBTL1BTKKCNA3DRD2 | |
| SCHEMBL3830184 | 0.75 | KMT2A (0.60) | KMT2AL3MBTL1BTKKCNA3DRD2 | |
| SCHEMBL15446618 | 0.75 | CKS1B (0.54) | CKS1BSKP1SKP2SUV39H2BTK | |
| SCHEMBL3200317 | 0.74 | KMT2A (0.56) | CKS1BSKP1SKP2KMT2AL3MBTL1 | |
| SCHEMBL3200309 | 0.74 | KMT2A (0.56) | CKS1BSKP1SKP2KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | CKS1B 774/4885SKP1 2807/4885SKP2 976/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | CKS1B 774/4885SKP1 2807/4885SKP2 976/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | CKS1B 774/4885SKP1 2807/4885SKP2 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.